సైన్స్ ఆర్కైవ్స్

నైరూప్య

A Double Observational Studies Research on the Advantages of Plerixafor for Mobilising Peripheral Blood Stem Cells before Autologous Transplantation

Katherine Barkey

Hematopoietic stem cells must be propelled from the bone marrow to the peripheral circulation for collecting prior to autologous stem cell transplantation (ASCT). Plerixafor, an antagonist of C-X-C chemokine receptor type 4, is employed to boost stem cell harvests. Plerixafor's impact on post-ASCT results, however, is still unknown.